Recombinant Human Anti-CD16 x Human Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-H214)

Recombinant Anti-CD16 x Anti-GD2 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD16 and anti-GD2 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD16 & GD2

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CD16

Gene ID

2214

UniProt ID

M9MML0

Alternative Names

FCGR3A; Fc fragment of IgG, low affinity IIIa, receptor (CD16a); CD16; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA; low affinity immunoglobulin gamma Fc region receptor III-A; FcγRIII; FcgammaRIIIA; CD16a antigen; fc-gamma RIII; Fc-gamma RIIIa; Fc-gamma RIII-alpha; igG Fc receptor III-2; Fc gamma receptor III-A; Fc-gamma receptor IIIb (CD16); neutrophil-specific antigen NA; Fc-gamma receptor III-2 (CD 16); immunoglobulin G Fc receptor III; Fc fragment of IgG, low affinity III, receptor for (CD16)

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD16 x Human Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-H214). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD16 x Human Anti-GD2 Bispecific Antibody (scIgG) (CAT#: SCIGG-H214)

Specifications

Targets

Customer Reviews and Q&As